Content - SAKK 19/16 is activated

SAKK 19/16 is activated

SAKK has activated a new trial for patients with metastatic KRAS-mutated non-small cell lung cancer.

This trial is investigating whether binimetinib in combination with standard chemotherapy pemetrexed and cisplatin, followed by maintenance therapy with binimetinib and pemetrexed, is effective and tolerated in patients with metastatic KRAS-mutated non-small cell lung cancer.

Non-small cell lung cancer is a type of cancer that grows and forms metastases more slowly than small cell lung cancer. In KRAS-mutated lung cancer the KRAS gene is mutated. Binimetinib is a targeted substance that inhibits the activation of KRAS-mutated tumour cells. This substance has been used worldwide in patients with various types of cancer, but not in combination with standard chemotherapy. In the SAKK 19/16 trial, the dosage of binimetinib will be determined for subsequent research projects.  

During the trial, we will also be collecting blood samples in order to obtain a better understanding of this disease, its prognosis and treatment. We intend to store this biological material in a biobank, because such residual material and the health-related data are very valuable for biomedical research.

All news